Cargando…
Treatment with b-AP15 to Inhibit UCHL5 and USP14 Deubiquitinating Activity and Enhance p27 and Cyclin E1 for Tumors with p53 Deficiency
Background: TP53 protein is lost or mutated in about half of all types of human cancers and small molecules to regulate mutant p53 repair, or interrupt ubiquitination degradation of p53 induced by E3-ubiquitin ligase Mdm2 have a potential application in clinical application. Methods: To inhibit the...
Autores principales: | Jiang, Zong-Yuan, Hong, Jiang, Zhang, Ju-Hua, Wang, Xiao-Feng, Ma, Yu-Shui, Xiong, Zhang-Xia, Sun, Hao-Ran, Cheng, Cong, Xie, Bang-Zhu, Liu, Ji-Bin, Ouyang, Yang-Gang, Fu, Da |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386868/ https://www.ncbi.nlm.nih.gov/pubmed/35971329 http://dx.doi.org/10.1177/15330338221119745 |
Ejemplares similares
-
MicroRNA-592 Inhibits the Growth of Ovarian Cancer Cells by Targeting
ERBB3
por: Jin, Qiong, et al.
Publicado: (2023) -
Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies
por: Li, Yang, et al.
Publicado: (2023) -
Predictive Value of FNA-Tg and TgAb in Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma
por: Wu, Xiaoli, et al.
Publicado: (2022) -
Isatuximab in the Treatment of Multiple Myeloma: A Review and
Comparison With Daratumumab
por: Shen, Fei, et al.
Publicado: (2022) -
Sequential Administrations of a Vascular-Disrupting Agent,
High-Intensity Focused Ultrasound, and a Radioactively labeled Necrosis Avid
Compound for Eradicating Solid Malignancies
por: Li, Yue, et al.
Publicado: (2022)